Patents Assigned to Vivus, Inc.
-
Patent number: 10058532Abstract: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.Type: GrantFiled: June 30, 2017Date of Patent: August 28, 2018Assignee: Vivus, Inc.Inventors: Wesley Day, Barbara Troupin
-
Patent number: 10028916Abstract: Formulations are provided for the oral administration of avanafil, a Type V phosphodiesterase inhibitor (“PDE V inhibitor”), and analogs thereof. The formulations are orally disintegrating tablets (ODTs) that rapidly dissolve or disintegrate in the oral cavity. The tablets contain an absorption enhancing composition that increases the duodenal absorption of the active agent, following transfer from the low pH environment of the stomach to the more basic pH of the duodenum. Methods for administering the active agent using the dosage forms are provided. The invention also encompasses a method of selecting components and compositions to incorporate in the formulations which will facilitate increased absorption of the active agent in the duodenum and thus serve as “absorption enhancing compositions” herein. Also provided are methods for manufacturing orally disintegrating tablets to optimize the physical properties of the dosage forms, particularly hardness and disintegration time.Type: GrantFiled: May 15, 2015Date of Patent: July 24, 2018Assignee: Vivus, Inc.Inventors: Calvin Theodore Broman, Eric Sheu
-
Patent number: 9724327Abstract: The present invention provides compositions and methods for delaying or preventing progression to type 2 diabetes mellitus in individuals with prediabetes and metabolic syndrome.Type: GrantFiled: October 8, 2014Date of Patent: August 8, 2017Assignee: Vivus, Inc.Inventors: Wesley Day, Barbara Troupin
-
Patent number: 9011906Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: GrantFiled: September 24, 2014Date of Patent: April 21, 2015Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 9011905Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: GrantFiled: September 24, 2014Date of Patent: April 21, 2015Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8895057Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: GrantFiled: October 8, 2013Date of Patent: November 25, 2014Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8895058Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: GrantFiled: October 8, 2013Date of Patent: November 25, 2014Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8802636Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: January 6, 2010Date of Patent: August 12, 2014Assignee: Vivus, Inc.Inventor: Thomas Najarian
-
Publication number: 20140094511Abstract: This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine.Type: ApplicationFiled: October 17, 2013Publication date: April 3, 2014Applicant: Vivus, Inc.Inventors: Leland F. Wilson, Peter Y. Tam, Thomas Najarian, Charles H. Bowden
-
Publication number: 20140088162Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.Type: ApplicationFiled: September 12, 2013Publication date: March 27, 2014Applicant: VIVUS, INC.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson, Craig Peterson
-
Publication number: 20140089470Abstract: A method or system for enabling client devices connected to a network to subscribe to a one or more multimedia signals available in a selection of bandwidths, based on an analysis of capabilities of the client, the quality of the connection, and the real-time changes in the ability of the client to process the signal.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: ViVu, Inc.Inventors: SivaKiran Venkata Yellamraju, Simha Sundeep Reddy Katasani
-
Patent number: 8626499Abstract: A method or system for enabling client devices connected to a network to subscribe to a one or more multimedia signals available in a selection of bandwidths, based on an analysis of capabilities of the client, the quality of the connection, and the real-time changes in the ability of the client to process the signal.Type: GrantFiled: July 20, 2010Date of Patent: January 7, 2014Assignee: ViVu, Inc.Inventors: SivaKiran Venkata Yellamraju, Simha Sundeep Reddy Katasani
-
Patent number: 8580299Abstract: The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.Type: GrantFiled: June 9, 2009Date of Patent: November 12, 2013Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson
-
Patent number: 8580298Abstract: A method for effecting weight loss by administering a combination of topiramate and phentermine is provided. The phentermine is generally administered in immediate release form, in a daily dose in the range of 2 mg to 8 mg, in combination with a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone. Methods for treating obesity, conditions associated with obesity, and other indications are also provided, as are compositions and dosage forms containing low doses of phentermine and topiramate, e.g., 3.75 mg phentermine and 23 mg topiramate.Type: GrantFiled: June 9, 2009Date of Patent: November 12, 2013Assignee: Vivus, Inc.Inventors: Thomas Najaraian, Peter Y. Tam, Leland F. Wilson
-
Publication number: 20130296324Abstract: The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.Type: ApplicationFiled: February 25, 2013Publication date: November 7, 2013Applicant: VIVUS, Inc.Inventor: Jerry M. Held
-
Patent number: 8536138Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.Type: GrantFiled: December 5, 2011Date of Patent: September 17, 2013Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson, Craig Peterson
-
Patent number: 8483284Abstract: Methods and apparatus for generating an interactive video stream from a plurality of multimedia components based on a state definition is disclosed. A plurality of multimedia components are retrieved in accordance with the state definition. The plurality of multimedia components are decoded. The plurality of multimedia components are retimed to a common frame rate. The multimedia components are then scaled and multiplexed into a multiplexed video stream, in accordance with the state definition.Type: GrantFiled: November 20, 2008Date of Patent: July 9, 2013Assignee: ViVu. Inc.Inventor: SivaKiran Venkata Yellamraju
-
Patent number: 8440671Abstract: The invention relates generally to novel pharmaceutical methods for the treatment of various conditions. Compositions comprising: at least one phosphodiesterase-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; a serotonin-norepinephrine reuptake inhibitor; a cholinesterase inhibitor; a dopamine agonist; or a medication suitable to increase the chemical concentrations of the neurotransmitters, selected from amino acids, monoamines, neuropeptides and other agents capable of primary neurotransmission in the synaptic clefts, and their use for treating a neurodegenerative disease in a subject. The invention also relates to: Compositions comprising: at least one phosphodiestersa-5-inhibitor in combination with one or more of the following medications: a selective serotonin reuptake inhibitor; or a cholinesterase inhibitor, and their use for treating damaged skin in a subject.Type: GrantFiled: May 19, 2008Date of Patent: May 14, 2013Assignee: Vivus, Inc.Inventor: Jerry M. Held
-
Publication number: 20120196881Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.Type: ApplicationFiled: December 5, 2011Publication date: August 2, 2012Applicant: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson, Craig Peterson
-
Patent number: 8071557Abstract: This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.Type: GrantFiled: June 13, 2007Date of Patent: December 6, 2011Assignee: Vivus, Inc.Inventors: Thomas Najarian, Peter Y. Tam, Leland F. Wilson, Craig Peterson